Fact check
“The reclassification of cannabis hinged on a change in attitude rather than a change in the underlying science.”
Reasoning
The Reason.com article cites a GAO report noting that the DEA's decision to reclassify cannabis reflected a shift in regulatory attitude, not a change in underlying science. This directly supports the claim.
On confidence: The primary source explicitly states that the reclassification of cannabis was driven by a change in attitude rather than new scientific evidence.
Important context
The claim pertains to the rationale behind cannabis's scheduling change under the Controlled Substances Act, emphasizing regulatory interpretation over scientific data.
Evidence
Supporting (1)
- Tier 1 — Primary sourceFederal drug scheduling relies on vague criteria, GAO report finds
identical, distinguished only by their intended use. By contrast, cocaine, fentanyl, and methamphetamine are all Schedule II drugs, regardless of whether they are dispensed by pharmacies based on medical prescriptions or purchased on the…
Contextual (3)
- Tier 1 — Primary sourceFederal drug scheduling relies on vague criteria, GAO report finds
abuse." But as a recent report from the Government Accountability Office (GAO) notes, the statute does not clearly define either criterion, opening the door to debatable and changeable regulatory judgments with far-reaching criminal…
- Tier 1 — Primary sourceFederal drug scheduling relies on vague criteria, GAO report finds
similar to the evidence that the Food and Drug Administration (FDA) demands to approve a drug for prescription use, the DEA's definition essentially equated "accepted medical use" with FDA approval. During the Biden administration, the HHS…
- Tier 1 — Primary sourceFederal drug scheduling relies on vague criteria, GAO report finds
cannabis illustrates that puzzle. When Congress enacted the CSA in 1970, it placed marijuana in Schedule I, and the Drug Enforcement Administration (DEA), which had the authority to reclassify drugs in consultation with the Department of…
Limitations
The assessment relies on a single source; additional independent analyses could further corroborate the claim. No independent origin corroborated this claim, so it cannot be verified and confidence cannot be high.
- Last verified:
- Oct 1, 2026, 4:49 AM CDT
- Pipeline:
- 2.1.0
- Claim type:
- Factual
Where this claim appeared
Hazy Drug Classification Criteria Invite Dubious Bureaucratic JudgmentsReason · Jacob Sullum